Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 671-681

  Oh, Yumin ^a,b   Swierczewska, Magdalena ^a,b   Kim, Tae Hyung ^a,b   Lim, Sung Mook ^c   Eom, Ha Na ^c   Park, Jae Hyung ^c   Na, Dong Hee ^d   Kim, Kwangmeyung ^e   Lee, Kang Choon ^c   Pomper, Martin G ^a,f   Lee, Seulki ^a,b,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Sungkyunkwan University   (South Korea)

^d Kyungpook National University   (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

^f Johns Hopkins University   (United States)

Author keywords

Apoptosis; Death receptors; Nanomedicine; TRAIL; TRAIL sensitizers

Indexed keywords

BIOLOGICAL MATERIALS; CELL DEATH; CELLS; DISEASES; DRUG PRODUCTS; HYALURONIC ACID; LIGANDS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POLYMERASE CHAIN REACTION; TISSUE; TOXICITY; TUMORS;

CELL VIABILITY ASSAYS; DEATH-RECEPTOR; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSIONS; THERAPEUTIC EFFICACY; TRAIL; TRAIL SENSITIZERS; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDS;

DIAGNOSIS;

DOXORUBICIN; HYALURONIC ACID; MESSENGER RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; CASPASE; MACROGOL DERIVATIVE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CHEMOSENSITIZATION; CONJUGATE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HALF LIFE TIME; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; HT-29 CELL LINE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HALF-LIFE; HCT116 CELLS; HEK293 CELLS; HT29 CELLS; HUMANS; HYALURONIC ACID; INJECTIONS, INTRAVENOUS; MICE, INBRED BALB C; MICE, NUDE; POLYETHYLENE GLYCOLS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949490107     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.014     Document Type: Article

References (43)

1. A. Ashkenazi, and R.S. Herbst To kill a tumor cell: the potential of proapoptotic receptor agonists J. Clin. Invest. 118 2008 1979 1990
2. R.W. Johnstone, A.J. Frew, and M.J. Smyth The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat. Rev. Cancer 8 2008 782 798
3. J.E. Allen, and W.S. El-Deiry Regulation of the human TRAIL gene Cancer Biol. Ther. 13 2012 1143 1151
4. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R.H. Schwall Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155 162
5. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh, and D.H. Lynch Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157 163
6. D.W. Stuckey, and K. Shah TRAIL on trial: preclinical advances in cancer therapy Trends Mol. Med. 19 2013 685 694
7. R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. O'Dwyer, M.S. Gordon, W. Novotny, M.A. Goldwasser, T.M. Tohnya, B.L. Lum, A. Ashkenazi, A.M. Jubb, and D.S. Mendelson Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28 2010 2839 2846
8. S. Leong, R.B. Cohen, D.L. Gustafson, C.J. Langer, D.R. Camidge, K. Padavic, L. Gore, M. Smith, L.Q. Chow, M. von Mehren, C. O'Bryant, S. Hariharan, S. Diab, N.L. Fox, R. Miceli, and S.G. Eckhardt Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study J. Clin. Oncol. 27 2009 4413 4421
9. J.C. Soria, Z. Mark, P. Zatloukal, B. Szima, I. Albert, E. Juhasz, J.L. Pujol, J. Kozielski, N. Baker, D. Smethurst, Y.J. Hei, A. Ashkenazi, H. Stern, L. Amler, Y. Pan, and F. Blackhall Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer J. Clin. Oncol. 29 2011 4442 4451
10. T. Trarbach, M. Moehler, V. Heinemann, C.H. Kohne, M. Przyborek, C. Schulz, V. Sneller, G. Gallant, and S. Kanzler Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer Br. J. Cancer 102 2010 506 512
11. L.Y. Dimberg, C.K. Anderson, R. Camidge, K. Behbakht, A. Thorburn, and H.L. Ford On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics Oncogene 32 2013 1341 1350
12. J. Lemke, S. von Karstedt, J. Zinngrebe, and H. Walczak Getting TRAIL back on track for cancer therapy Cell Death Differ. 21 2014 1350 1364
13. T. Newsom-Davis, S. Prieske, and H. Walczak Is TRAIL the holy grail of cancer therapy? Apoptosis 14 2009 607 623
14. C.T. Hellwig, and M. Rehm TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies Mol. Cancer Ther. 11 2012 3 13
15. C. Voelkel-Johnson TRAIL-mediated signaling in prostate, bladder and renal cancer Nat. Rev. Urol. 8 2011 417 427
16. S.K. Kelley, L.A. Harris, D. Xie, L. Deforge, K. Totpal, J. Bussiere, and J.A. Fox Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J. Pharmacol. Exp. Ther. 299 2001 31 38
17. A. Ashkenazi, P. Holland, and S.G. Eckhardt Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) J. Clin. Oncol. 26 2008 3621 3630
18. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
19. T.M. Ganten, R. Koschny, J. Sykora, H. Schulze-Bergkamen, P. Buchler, T.L. Haas, M.B. Schader, A. Untergasser, W. Stremmel, and H. Walczak Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs Clin. Cancer Res. 12 2006 2640 2646
20. G. Pasut, and F.M. Veronese PEG conjugates in clinical development or use as anticancer agents: an overview Adv. Drug Deliv. Rev. 61 2009 1177 1188
21. S.Y. Chae, T.H. Kim, K. Park, C.H. Jin, S. Son, S. Lee, Y.S. Youn, K. Kim, D.G. Jo, I.C. Kwon, X. Chen, and K.C. Lee Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand Mol. Cancer Ther. 9 2010 1719 1729
22. T.H. Kim, Y.S. Youn, H.H. Jiang, S. Lee, X. Chen, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects Bioconjug. Chem. 22 2011 1631 1637
23. K.G. Drosopoulos, M.L. Roberts, L. Cermak, T. Sasazuki, S. Shirasawa, L. Andera, and A. Pintzas Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway J. Biol. Chem. 280 2005 22856 22867
24. C. Stolfi, R. Caruso, E. Franze, A. Rizzo, A. Rotondi, I. Monteleone, M.C. Fantini, F. Pallone, and G. Monteleone 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression Mol. Cancer Ther. 10 2011 1969 1981
25. S. Lacour, O. Micheau, A. Hammann, V. Drouineaud, J. Tschopp, E. Solary, and M.T. Dimanche-Boitrel Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells Oncogene 22 2003 1807 1816
26. J. Vrielink, M.S. Heins, R. Setroikromo, E. Szegezdi, M.M. Mullally, A. Samali, and W.J. Quax Synthetic constrained peptide selectively binds and antagonizes death receptor 5 FEBS J. 277 2010 1653 1665
27. F. Muhlenbeck, E. Haas, R. Schwenzer, G. Schubert, M. Grell, C. Smith, P. Scheurich, and H. Wajant TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways J. Biol. Chem. 273 1998 33091 33098
28. N.G. Dolloff, P.A. Mayes, L.S. Hart, D.T. Dicker, R. Humphreys, and W.S. El-Deiry Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation Sci. Transl. Med. 3 2011 86ra50
29. L. Fu, Y.D. Lin, H.A. Elrod, P. Yue, Y. Oh, B. Li, H. Tao, G.Z. Chen, D.M. Shin, F.R. Khuri, and S.Y. Sun c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL Mol. Cancer 9 2010 315
30. B.L. Bennett, D.T. Sasaki, B.W. Murray, E.C. O'Leary, S.T. Sakata, W. Xu, J.C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S.S. Bhagwat, A.M. Manning, and D.W. Anderson SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase Proc. Natl. Acad. Sci. U. S. A. 98 2001 13681 13686
31. K.Y. Choi, E.J. Jeon, H.Y. Yoon, B.S. Lee, J.H. Na, K.H. Min, S.Y. Kim, S.J. Myung, S. Lee, X. Chen, I.C. Kwon, K. Choi, S.Y. Jeong, K. Kim, and J.H. Park Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer Biomaterials 33 2012 6186 6193
32. K.Y. Choi, H. Chung, K.H. Min, H.Y. Yoon, K. Kim, J.H. Park, I.C. Kwon, and S.Y. Jeong Self-assembled hyaluronic acid nanoparticles for active tumor targeting Biomaterials 31 2010 106 114
33. K.Y. Choi, H.Y. Yoon, J.H. Kim, S.M. Bae, R.W. Park, Y.M. Kang, I.S. Kim, I.C. Kwon, K. Choi, S.Y. Jeong, K. Kim, and J.H. Park Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy ACS Nano 5 2011 8591 8599
34. K.Y. Choi, G. Saravanakumar, J.H. Park, and K. Park Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer Colloids Surf. B: Biointerfaces 99 2012 82 94
35. M. Swierczewska, K.Y. Choi, E.L. Mertz, X. Huang, F. Zhang, L. Zhu, H.Y. Yoon, J.H. Park, A. Bhirde, S. Lee, and X. Chen A facile, one-step nanocarbon functionalization for biomedical applications Nano Lett. 12 2012 3613 3620
36. G. Liu, K.Y. Choi, A. Bhirde, M. Swierczewska, J. Yin, S.W. Lee, J.H. Park, J.I. Hong, J. Xie, G. Niu, D.O. Kiesewetter, S. Lee, and X. Chen Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate Angew. Chem. Int. Ed. Engl. 51 2012 445 449
37. H.Y. Yoon, H.R. Kim, G. Saravanakumar, R. Heo, S.Y. Chae, W. Um, K. Kim, I.C. Kwon, J.Y. Lee, D.S. Lee, J.C. Park, and J.H. Park Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting J. Control. Release 172 2013 653 661
38. A. Rahman, D. Carmichael, M. Harris, and J.K. Roh Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes Cancer Res. 46 1986 2295 2299
39. J. Jiang, X. Liu, L. Deng, P. Zhang, G. Wang, S. Wang, H. Liu, and Y. Su GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial Eur. J. Pharmacol. 740 2014 722 732
40. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
41. S.C. Ghosh, S. Neslihan Alpay, and J. Klostergaard CD44: a validated target for improved delivery of cancer therapeutics Expert Opin. Ther. Targets 16 2012 635 650
42. J. Hrkach, D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J.J. Song, Y.H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P.W. Kantoff, N.H. Bander, C. Sweeney, O.C. Farokhzad, R. Langer, and S. Zale Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 4 2012 128ra139
43. C.A. Schutz, L. Juillerat-Jeanneret, H. Mueller, I. Lynch, and M. Riediker Therapeutic nanoparticles in clinics and under clinical evaluation Nanomedicine (London) 8 2013 449 467